Jazz To Acquire Cannabinoid Drug Company GW Pharma For $7.2B

In the first big-ticket biopharma M&A of the year, Jazz Pharmaceuticals PLC JAZZ announced a deal to buy cannabinoid drug company GW Pharmaceuticals PLC- ADR GWPH.

The Jazz-GW Pharma Deal: Jazz announced a definitive agreement to buy GW Pharma for a total consideration of $220 per ADS in cash and stock, with $200 in cash and $20 in Jazz shares. The per-share value represents about 50.4% premium over the $146.25 per share at which GW Pharma closed Tuesday.

Total consideration would be $7.2 billion, or $6.7 billion, net of GW Pharma's cash. The deal has been unanimously approved by boards of both companies.

Jazz expects to fund the cash portion of the deal through a combination of cash on hand and debt financing. The company said it has obtained fully committed debt financing from BofA Securities and JPMorgan Securities.

The closing of the deal is subject to approval by GW Pharma shareholders, sanction by the High Court of Justice of England and Wales and other customary closing conditions. The transaction is expected to close in the second quarter of 2021.

Related Link: Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates

The Jazz-GW Pharma Deal Logic: Upon close of the transaction, the combined company will be a leader in neuroscience with a global commercial and operational footprint, Jazz said in the statement.

The deal is expected to add a third high-growth commercial franchise for Jazz.

"Jazz is proud of our leadership position in sleep medicines and rapidly growing oncology business. We are excited to add GW's industry-leading cannabinoid platform, innovative pipeline and products, which will strengthen and broaden our neuroscience portfolio, further diversify our revenue and drive sustainable, long-term value creation opportunities," said Bruce Cozadd, CEO of Jazz.

GW Pharma's lead product, plant-derived Epidiolex oral solution, is approved in patients one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex.

This product has also been approved, in Europe under the tradename Epidiolex in patients two years of age and older for the adjunctive treatment of seizures associated with LGS and Dravet syndrome in conjunction with clobazam.

Additionally, GW Pharma's pipeline includes Phase 3 asset nabiximols for treatment of spasticity associated with multiple sclerosis and spinal cord injury, as well as earlier-stage cannabinoid product candidates for autism and schizophrenia.

The companies expect the combination to provide double-digit revenue growth and be accretive in the first full year of combined operations and substantially accretive thereafter.

In premarket trading, Jazz shares were slipping 4.63% to $150, while GW Pharma stock was jumping 47.01% to $215.

Posted In: BiotechCannabisM&ANewsHealth CareTop StoriesMarketsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.